SAN DIEGO –(BUSINESS WIRE)–Mar. 15, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024 , the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares
News Category: General News
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
SAN DIEGO –(BUSINESS WIRE)–Mar. 13, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time . The conference will be held virtually. A live webcast of Acadia’s presentation will be
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
SAN DIEGO –(BUSINESS WIRE)–Feb. 29, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44 th Annual Health Care Conference on Wednesday, March 6, 2024 , at 11:10 a.m. Eastern Time . A live webcast of Acadia’s presentation will be accessible
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO –(BUSINESS WIRE)–Feb. 21, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 15, 2024 , the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,823
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Company to host conference call and webcast on Tuesday, February 27, 2024 , at 4:30 p.m. Eastern Time SAN DIEGO –(BUSINESS WIRE)–Feb. 13, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2023 financial results on Tuesday, February
Acadia Announces Additions to Executive Team
SAN DIEGO –(BUSINESS WIRE)–Jan. 30, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team. Jennifer J. Rhodes is joining the company as Executive Vice President, Chief Legal Officer and Secretary, and Kimberly J.
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO –(BUSINESS WIRE)–Jan. 19, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 9, 2024 , the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 39,169 shares
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
SAN DIEGO –(BUSINESS WIRE)–Jan. 18, 2024– Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D ., M.S.P.H. Serge passed away peacefully on December 29, 2023 , following a prolonged illness.
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
SAN DIEGO –(BUSINESS WIRE)–Dec. 21, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 , at 9:00 a.m. Pacific Time , followed by a question and answer session.
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO –(BUSINESS WIRE)–Dec. 18, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 13, 2023 , the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 33,647